Pharma

FDA clears the first at‑home subcutaneous IL‑6R treatment for TED; Phase III SatraGO‑2 showed marked proptosis and diplopia improvements and safety consistent with prior NMOSD data.

CHMP backs an oral RAS inhibitor for adults with metastatic pancreatic adenocarcinoma after prior therapy; phase‑3 data show doubled median survival versus chemotherapy and review took under 150 days.

Phase 3 GALAXI 2 and 3 Week 144 LTE data report high rates of clinical, corticosteroid‑free and endoscopic remission with two maintenance regimens; 74% remained on treatment at three years.

Phase 3 intismeran combo improved recurrence‑free and distant metastasis‑free survival in resected stage IIB–IV melanoma; sac‑TMT and KEYNOTE‑C93 report pivotal endometrial cancer findings; >90 additional abstracts.

Sustained vision gains and reduced macular thickness at Week 52; ~2/3 avoided retreatment after Week 16, most needing only one additional injection; safety profile consistent.

Oral helicase‑primase inhibitor pritelivir is the first novel‑mechanism FDA‑approved HSV therapy in ~30 years; Phase 3 showed 63% vs 34% healing by Day 28. US availability expected before end of 2026.

Vamikibart showed sustained vision gains and reduced macular thickness at 52 weeks in MEERKAT and SANDCAT; FDA has accepted the BLA with a decision due by July 2027.

Remigromig met non-inferiority for mean BCVA change versus monthly ranibizumab at one year in DME; higher rates of PDR-related adverse events and discontinuations were reported.

Live attenuated vaccine cuts clinical signs and viraemia from three weeks post‑vaccination and confers protection for one year; authorised under exceptional circumstances; side effects are uncommon.

Positive opinions for Bovilis Lumpyvax and Stemyca; Mirataz SPC updated for overdose effects; Vaxxitek MA extended one year; Vetmedin re‑examination concluded positive by majority.